Sayedeh-Zahra Kazemi-Harikandei, Amirali Karimi, Seyed Mohammad Tavangar
{"title":"Clinical Perspectives on the Histomolecular Features of the Pancreatic Precursor Lesions: A Narrative Review.","authors":"Sayedeh-Zahra Kazemi-Harikandei, Amirali Karimi, Seyed Mohammad Tavangar","doi":"10.34172/mejdd.2024.387","DOIUrl":null,"url":null,"abstract":"<p><p>Pancreatic cancer (PC) is a lethal cancer with poor prognoses. Identifying and characterizing pancreatic cystic lesions (PCLs) in the early detection and follow-up plans is thought to help detect pancreatic malignancy. Besides, the molecular features of PCLs are thought to unravel potentials for targeted therapies. We present a narrative review of the existing literature on the role of PCLs in the early detection, risk stratification, and medical management of PC. High-grade intraductal papillary mucinous neoplasms (IPMN) and pancreatic intraepithelial neoplasia (PanIN) stage III are high-risk lesions for developing PC. These lesions often require thorough histomolecular characterization using endoscopic ultrasound (EUS), before a surgical decision is made. EUS is also useful in the risk assessment of PCLs with tentative plans-for instance, in branch-duct IPMNs (BD-IPMN)- where the final decision might change. Besides the operative decisions, recent improvements in the application of targeted therapies are expected to improve survival measures. Knowledge of molecular features has helped develop targeted therapies. In summary, the histomolecular characterization of PCLs is helpful in optimizing management plans in PC. Further improvements are still needed for the broad application of this knowledge in the clinical setting.</p>","PeriodicalId":18517,"journal":{"name":"Middle East Journal of Digestive Diseases","volume":"16 3","pages":"136-146"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459284/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Digestive Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/mejdd.2024.387","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Pancreatic cancer (PC) is a lethal cancer with poor prognoses. Identifying and characterizing pancreatic cystic lesions (PCLs) in the early detection and follow-up plans is thought to help detect pancreatic malignancy. Besides, the molecular features of PCLs are thought to unravel potentials for targeted therapies. We present a narrative review of the existing literature on the role of PCLs in the early detection, risk stratification, and medical management of PC. High-grade intraductal papillary mucinous neoplasms (IPMN) and pancreatic intraepithelial neoplasia (PanIN) stage III are high-risk lesions for developing PC. These lesions often require thorough histomolecular characterization using endoscopic ultrasound (EUS), before a surgical decision is made. EUS is also useful in the risk assessment of PCLs with tentative plans-for instance, in branch-duct IPMNs (BD-IPMN)- where the final decision might change. Besides the operative decisions, recent improvements in the application of targeted therapies are expected to improve survival measures. Knowledge of molecular features has helped develop targeted therapies. In summary, the histomolecular characterization of PCLs is helpful in optimizing management plans in PC. Further improvements are still needed for the broad application of this knowledge in the clinical setting.
胰腺癌(PC)是一种预后不良的致命癌症。在早期检测和随访计划中识别胰腺囊性病变(PCL)并确定其特征,被认为有助于发现胰腺恶性肿瘤。此外,胰腺囊肿的分子特征也被认为可以揭示靶向治疗的潜力。我们就 PCL 在 PC 早期检测、风险分层和医疗管理中的作用对现有文献进行了叙述性综述。高级别导管内乳头状粘液瘤(IPMN)和胰腺上皮内瘤变(PanIN)III 期是罹患 PC 的高危病变。在做出手术决定之前,通常需要使用内镜超声(EUS)对这些病变进行彻底的组织分子鉴定。EUS 还有助于对暂定计划的 PCL 进行风险评估--例如分支导管 IPMN(BD-IPMN)--在这种情况下,最终决定可能会改变。除手术决策外,近期靶向疗法的应用也有望提高生存率。对分子特征的了解有助于开发靶向疗法。总之,PCL 的组织分子特征有助于优化 PC 的治疗方案。要将这些知识广泛应用于临床,还需要进一步的改进。